Natural History of Adrenal Steroidogenesis in Autoimmune Addison's Disease Following Diagnosis and Treatment.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 04 12 2019
accepted: 15 04 2020
pubmed: 18 4 2020
medline: 9 2 2021
entrez: 18 4 2020
Statut: ppublish

Résumé

The natural history of adrenal function in autoimmune Addison disease once diagnosed and treated has not been systematically studied, but several case reports of recovery from established adrenal failure suggest it may not be uniform. To ascertain steroidogenic function in autoimmune Addison disease immediately following diagnosis and during prolonged treatment. We studied peak serum cortisol in response to ACTH1-24 in 20 newly diagnosed autoimmune Addison disease patients at first presentation and then again within a month. We also studied 37 patients with established Addison disease (for between 7 months and 44 years) in a medication-free state, measuring peak serum cortisol responses to ACTH1-24 and the urine LC-MS steroid metabolome. Adrenal steroidogenesis declined rapidly after steroid replacement treatment for newly diagnosed Addison disease was started, with a peak serum cortisol falling from 138 ± 19 nmol/L (SEM) at presentation to 63 ± 13 nmol/L over 4 weeks (P < 0.003).Six of 37 participants (16%) with established Addison disease had detectable serum cortisol and urine glucocorticoid and mineralocorticoid metabolites during repeat testing, indicating variable degrees of residual adrenal function. Autoimmune Addison disease is a heterogeneous condition, showing a rapid decline in adrenal steroidogenesis during the first few weeks following diagnosis, but low-level residual function in a minority of patients, which appears to persist for many years.

Identifiants

pubmed: 32300791
pii: 5821191
doi: 10.1210/clinem/dgaa187
pmc: PMC7250207
pii:
doi:

Substances chimiques

Cosyntropin 16960-16-0
Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : G0900001
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701632
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J002526/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14101
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701632
Pays : United Kingdom

Informations de copyright

© Endocrine Society 2020.

Références

QJM. 2012 Nov;105(11):1113-5
pubmed: 21908862
Clin Endocrinol (Oxf). 2019 Sep;91(3):383-390
pubmed: 31059146
Clin Endocrinol (Oxf). 2011 Apr;74(4):434-7
pubmed: 21114513
J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84
pubmed: 21917861
J Endocrinol Invest. 2008 Jul;31(7):672-4
pubmed: 18787390
J Clin Endocrinol Metab. 2014 Jan;99(1):111-8
pubmed: 24170102
Endocr Connect. 2018 May;7(5):617-629
pubmed: 29622661
J Intern Med. 2014 Feb;275(2):104-15
pubmed: 24330030
Front Endocrinol (Lausanne). 2015 May 06;6:70
pubmed: 25999916
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044
Exp Clin Endocrinol Diabetes. 2007 Sep;115(8):530-2
pubmed: 17853338
Am J Med Sci. 2010 Jun;339(6):525-31
pubmed: 20400889
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31863094
Eur J Endocrinol. 2019 Jan 1;:
pubmed: 30608902
Nat Rev Endocrinol. 2012 Jan 31;8(5):306-16
pubmed: 22290360
J Clin Endocrinol Metab. 2012 Oct;97(10):E1927-32
pubmed: 22767640
Clin Endocrinol (Oxf). 2019 Jan;90(1):241-249
pubmed: 30358903
J Clin Endocrinol Metab. 2001 Feb;86(2):675-8
pubmed: 11158030
Immunol Today. 1995 Jun;16(6):289-94
pubmed: 7662098
Mol Cell Endocrinol. 2011 Apr 10;336(1-2):206-12
pubmed: 21094677
J Clin Endocrinol Metab. 2016 Nov;101(11):3865-3869
pubmed: 27680876
Presse Med. 2012 Dec;41(12 P 2):e626-35
pubmed: 23177474
Endocrinol Diabetes Metab Case Rep. 2013;2013:130070
pubmed: 24683477

Auteurs

Catherine Napier (C)

Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne.
Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, UK.

Kathleen Allinson (K)

Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne.
Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, UK.

Earn H Gan (EH)

Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne.
Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, UK.

Anna L Mitchell (AL)

Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne.
Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, UK.

Lorna C Gilligan (LC)

Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.
NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.

Angela E Taylor (AE)

Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.
NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.

Wiebke Arlt (W)

Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.
NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.

Simon H S Pearce (SHS)

Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne.
Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH